Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer

Azevedo, Rita; Soares, Janine; Gaiteiro, Cristiana; Peixoto, Andreia; Lima, Luís; Ferreira, Dylan; Relvas-Santos, Marta; Fernandes, Elisabete; Tavares, Ana; Cotton, Sofia; Daniel‐da‐Silva, Ana L.; Santos, Lúcio Lara; Vitorino, Rui; Amado, Francisco; Ferreira, José Alexandre

doi:10.1016/j.talanta.2018.03.028

Cited by 31 publications

(22 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a dozen urinary biomarkers for BCa including the BCa stem-cell marker CD44 (8), the nuclear matrix protein 22 (NMP22) (9), the fibroblast growth factor receptor 3 (FGFR3) (9), the BCa-Specific Antigen-1 (BLCA-1) (10), cathepsin D (11), podoplanin (12), Cystatin C (13), BLCA-4, CYFRA 21-1 and Survivin (14). Several of them such as BLCA-1 (10), podoplanin (12) and Cystatin C (13) were also tested as blood serum biomarkers for BCa.…”

Section: Introductionmentioning

confidence: 99%

Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis

et al. 2019

View full text Add to dashboard Cite

Bladder cancer (BCa) is the ninth most common cancer in the world and its early detection is crucial for successful therapy. Unfortunately, there are no satisfactory tools to detect BCa at early stages and BCa's confirmation muscle-invasive. The search for a suitable biomarker is therefore necessary and aromatase is a potential candidate. The purpose of the current study was to determine if aromatase serves as a biomarker of BCa. A Surface Plasmon Resonance Imaging biosensor was applied for the quantification and determination of aromatase. A total of 3 µl blood plasma was used for a single measurement. The results revealed that the aromatase concentration in the plasma of patients with BCa (n=78) ranged from 17.41-57.44 ng/ml. The range determined in healthy donors (n=18) was 2.59-7.74 ng/ml. Additionally, it was revealed that muscle invasive BCa samples exhibited elevated, statistically significant (P= 0.01) average aromatase concentrations in blood plasma (38.64 ng/ml) when compared with non-muscle invasive samples (29.83 ng/ml). The results demonstrated that plasma aromatase may serve as an excellent bimarker of BCa with 100% sensitivity, 100% selectivity and an area under the curve value of the reciever operating characteristic curve equal to 1.0. Furthermore, the marker differenciated between muscle-invasive and non muscle-invasive BCa with a sensitivity of 60% and a specificity of 81%. In conclusion, aromatase may serve a role in bladder tumorigenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Overexpression of urinary levels of SNAIL were shown to be an independent prognostic factor for tumor recurrence in NMIBC [ 76 ]. Urinary CD44 was elevated in high-grade MIBC based on glycan-affinity glycoproteomics nanoplatforms [ 77 ].…”

Section: Human Specimens-based Proteomics Biomarkersmentioning

confidence: 99%

“…Proteomics markers identified in different human samples are summarized in Table 4 [ 53 55 57 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 ].…”

Section: Human Specimens-based Proteomics Biomarkersmentioning

confidence: 99%

Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist

et al. 2020

View full text Add to dashboard Cite

At present, proteomic methods have successfully identified potential biomarkers of urological malignancies, such as prostate cancer (PC), bladder cancer (BC), and renal cell carcinoma (RCC), reflecting different numbers of key cellular processes, including extracellular environment modification, invasion and metastasis, chemotaxis, differentiation, metabolite transport, and apoptosis. The potential application of proteomics in the detection of clinical markers of urological malignancies can help improve patient assessment through early cancer detection, prognosis, and treatment response prediction. A variety of proteomic studies have already been carried out to find prognostic BC biomarkers, and a large number of potential biomarkers have been reported. It is worth noting that proteomics research has not been applied to the study of predictive markers; this may be due to the incompatibility between the number of measured variables and the available sample size, which has become particularly evident in the study of therapeutic response. On the contrary, prognostic correlation is more common, which is also reflected in existing research. We are now entering an era of clinical proteomics. Driven by proteomic-based workflows, computing tools, and the applicability of cross-correlation of proteomic data, it is now feasible to use proteomic analysis to support personalized medicine. In this paper, we will summarize the current emerging technologies for advanced discovery, targeted proteomics, and proteomic applications in BC, particularly in discovery of human-based biomarkers.

show abstract

“…Snail overexpression represents an independent prognostic factor for tumor recurrence in NMIBC ( 45 ). Finally, specific glycoproteins were identified by glycan-affinity glycoproteomics nanoplatforms in the urine of low- and high-grade NMIBC; among these, increased urinary CD44 levels were evidenced in high-grade MIBC ( 46 ).…”

Section: Proteomic and Peptidomic Analysismentioning

confidence: 99%

Urinary Markers in Bladder Cancer: An Update

et al. 2018

View full text Add to dashboard Cite

Bladder cancer (BC) is ones of the most common cancer worldwide. It is classified in muscle invasive (MIBC) and muscle non-invasive (NMIBC) BC. NMIBCs frequently recur and progress to MIBCs with a reduced survival rate and frequent distant metastasis. BC detection require unpleasant and expensive cystoscopy and biopsy, which are often accompanied by several adverse effects. Thus, there is an urgent need to develop novel diagnostic methods for initial detection and surveillance in both MIBCs and NMIBCs. Multiple urine-based tests approved by FDA for BC detection and surveillance are commercially available. However, at present, sensitivity, specificity and diagnostic accuracy of these urine-based assays are still suboptimal and, in the attend to improve them, novel molecular markers as well as multiple-assays must to be translated in clinic. Now there are growing evidence toward the use of minimally invasive “liquid biopsy” to identify biomarkers in urologic malignancy. DNA- and RNA-based markers in body fluids such as blood and urine are promising potential markers in diagnostic, prognostic, predictive and monitoring urological malignancies. Thus, circulating cell-free DNA, DNA methylation and mutations, circulating tumor cells, miRNA, IncRNA and mRNAs, cell-free proteins and peptides, and exosomes have been assessed in urine specimens. However, proteomic and genomic data must to be validated in well-designed multicenter clinical studies, before to be employed in clinic oncology.

show abstract

Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer

Cited by 31 publications

References 49 publications

Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis

Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis

Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist

Urinary Markers in Bladder Cancer: An Update

Contact Info

Product

Resources

About